Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2023 09:00 ET | Source: Parion Sciences

Parion Sciences Announces Publication of Phase 2 CLEAN-PCD Study in The Lancet Respiratory Medicine

Published Phase 2 Study findings demonstrate safety and efficacy of idrevloride in hypertonic saline for treatment of primary ciliary dyskinesiaAbstract to be presented at 2023 European Respiratory...
October 25, 2016 08:14 ET | Source: Parion Sciences

Parion Sciences Announces Presentation of Clinical Data with Novel Pulmonary Delivery Device at the 2016 North American Cystic Fibrosis Conference

DURHAM, N.C., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced that an abstract from its...
July 26, 2016 07:59 ET | Source: Parion Sciences

Parion Sciences Announces Initiation of Phase 2 Clinical Trial of P-321 for the Treatment of Dry Eye Disease

DURHAM, N.C,, July 26, 2016 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today it has initiated a...
May 02, 2016 08:02 ET | Source: Parion Sciences

Parion Sciences Announces the Presentation of Clinical Data on P-321 Ophthalmic Solution for the treatment of Dry Eye Disease at the Association for Research in Vision and Ophthalmology (ARVO 2016)

DURHAM, N.C., May 02, 2016 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and epithelial diseases, announced today the...
January 19, 2016 08:00 ET | Source: Parion Sciences

Ceva and Zoion Pharma Announce Collaboration to Develop Epithelial Sodium Channel Blockers to Treat Veterinary Ocular Surface Diseases

LIBOURNE, France and DURHAM, N.C., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Ceva Santé Animale and Zoion Pharma Inc. announced today that they have entered into a collaboration to develop an epithelial...
October 05, 2015 08:12 ET | Source: Parion Sciences

Parion Sciences Announces Upcoming Presentations of Data at the North American Cystic Fibrosis Conference Being Held October 8 through 10, 2015

Data From Preclinical and Clinical Research on P-1037(VX-371) to be PresentedAdditional Data Presentation Includes a Review of a Novel in Silico Approach Towards Identification of CFTR...
September 10, 2015 09:35 ET | Source: Parion Sciences

CLEAN-CF Clinical Trial Expanded to Include Pediatric Cystic Fibrosis Population

DURHAM, N.C., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today that the CLEAN-CF...
June 04, 2015 16:01 ET | Source: Parion Sciences

Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases

-ENaC inhibition aims to restore or improve hydration of cell surfaces in the lungs to improve lung function- -Parion to receive $80 million up-front payment with potential for additional development...
May 22, 2015 09:28 ET | Source: Parion Sciences

Parion Sciences Receives 2015 Life Sciences Award as “Best Late Stage Product Development” Company

DURHAM, N.C., May 22, 2015 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today that it was awarded the...
May 06, 2015 09:52 ET | Source: Parion Sciences

Parion Sciences Announces Initiation of Phase 2 Clinical Study of P-1037 for the Treatment of Cystic Fibrosis

DURHAM, N.C., May 6, 2015 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today it has begun enrollment of...